Revance Therapeutics Stock Forecast, Price & News

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

Is Revance Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics or view top-rated stocks.

How has Revance Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RVNC stock has decreased by 31.2% and is now trading at $12.36.
View which stocks have been most impacted by COVID-19.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for Revance Therapeutics.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the Zacks' consensus estimate of ($1.15) by $0.05. The biopharmaceutical company earned $19.75 million during the quarter, compared to analysts' expectations of $20.03 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 128.23% and a negative net margin of 470.81%. During the same period in the prior year, the firm posted ($1.34) earnings per share.
View Revance Therapeutics' earnings history.

What price target have analysts set for RVNC?

5 analysts have issued twelve-month target prices for Revance Therapeutics' stock. Their forecasts range from $17.00 to $36.00. On average, they anticipate Revance Therapeutics' share price to reach $23.60 in the next year. This suggests a possible upside of 90.9% from the stock's current price.
View analysts' price targets for Revance Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:

• Mark J. Foley, Chief Executive Officer & Director (LinkedIn Profile)
• Dustin Sjuts, President
• Abhay Joshi, COO & President-Research & Development
• Tobin C. Schilke, Chief Financial Officer
• Azita Nejad, Senior Vice President-Technical Operations

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

Who are some of Revance Therapeutics' key competitors?

Some companies that are related to Revance Therapeutics include Hypera (HYPMY), Cerevel Therapeutics (CERE), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), CureVac (CVAC), Karuna Therapeutics (KRTX), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Amicus Therapeutics (FOLD), Insmed (INSM) and Emergent BioSolutions (EBS).
View all of RVNC's competitors.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Aries Wealth Management (0.02%), Denali Advisors LLC (0.01%), Future Financial Wealth Managment LLC (0.00%) and Cutler Group LP (0.00%). Company insiders that own Revance Therapeutics stock include Angus C Russell, Aubrey Rankin, Dwight Moxie and Mark J Foley.
View institutional ownership trends for Revance Therapeutics.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was bought by a variety of institutional investors in the last quarter, including Aries Wealth Management, Denali Advisors LLC, Future Financial Wealth Managment LLC, and Cutler Group LP. Company insiders that have bought Revance Therapeutics stock in the last two years include Angus C Russell, Aubrey Rankin, and Mark J Foley.
View insider buying and selling activity for Revance Therapeutics or or view top insider-buying stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $12.36.

How much money does Revance Therapeutics make?

Revance Therapeutics has a market capitalization of $887.39 million and generates $15.32 million in revenue each year. The biopharmaceutical company earns $-282.09 million in net income (profit) each year or ($4.49) on an earnings per share basis.

How many employees does Revance Therapeutics have?

Revance Therapeutics employs 470 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

Where are Revance Therapeutics' headquarters?

Revance Therapeutics is headquartered at 7555 GATEWAY BLVD., NEWARK CA, 94560.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at [email protected], or via fax at 510-742-3401.